Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy
出版年份 2017 全文链接
标题
Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy
作者
关键词
-
出版物
Scientific Reports
Volume 7, Issue 1, Pages -
出版商
Springer Nature
发表日期
2017-02-16
DOI
10.1038/srep42713
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Evaluation of HER2/neu Status by Immunohistochemistry Using Computer-Based Image Analysis and Correlation With Gene Amplification by Fluorescence In Situ Hybridization Assay: A 10-Year Experience and Impact of Test Standardization on Concordance Rate
- (2015) Venetia R. Sarode et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2
- (2015) Stéphane Oudard et al. EUROPEAN JOURNAL OF CANCER
- Analysis of different HER-2 mutations in breast cancer progression and drug resistance
- (2015) Zijia Sun et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer
- (2015) Tetsutaro Hayashi et al. JOURNAL OF UROLOGY
- Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer
- (2015) J. Tschui et al. VIRCHOWS ARCHIV
- Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
- (2014) Woonyoung Choi et al. CANCER CELL
- Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
- (2014) J. S. Damrauer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades
- (2013) Pascal Zehnder et al. BJU INTERNATIONAL
- Level ofHER2Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab
- (2013) Carlos Gomez-Martin et al. JOURNAL OF CLINICAL ONCOLOGY
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- A Molecular Taxonomy for Urothelial Carcinoma
- (2012) G. Sjodahl et al. CLINICAL CANCER RESEARCH
- A single-sample microarray normalization method to facilitate personalized-medicine workflows
- (2012) Stephen R. Piccolo et al. GENOMICS
- Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
- (2012) Harry D. Bear et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
- (2012) Ron Bose et al. Cancer Discovery
- Exon array data analysis using Affymetrix power tools and R statistical software
- (2011) H. E. Lockstone BRIEFINGS IN BIOINFORMATICS
- Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer
- (2011) Mark Barok et al. CANCER LETTERS
- Her2 Amplification is Significantly More Frequent in Lymph Node Metastases From Urothelial Bladder Cancer Than in the Primary Tumours
- (2011) Achim Fleischmann et al. EUROPEAN UROLOGY
- Kuhn's Paradigms: Are Those Closest to Treating Bladder Cancer the Last to Appreciate the Paradigm Shift?
- (2011) Dean F. Bajorin et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Implications of Altered Human Epidermal Growth Factor Receptors (HERs) in Gastric Carcinomas: HER2 and HER3 Are Predictors of Poor Outcome
- (2011) Maria D. Begnami et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib
- (2011) Rama Krishna Kancha et al. PLoS One
- A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
- (2011) A. Bertotti et al. Cancer Discovery
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing
- (2010) Josef Rüschoff et al. VIRCHOWS ARCHIV
- A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma
- (2009) Christian Wülfing et al. CANCER
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started